Advertisement

Topics

J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

13:52 EDT 19 Oct 2016 | SCRIP

Pharma says pipeline is poised to continue growth with 10 NMEs to be approved between 2015-2019 that could produce blockbuster...

      

Related Stories

 

Original Article: J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches

NEXT ARTICLE

More From BioPortfolio on "J&J Relying On Oncology As Growth Driver, Led By Solid Imbruvica, Darzalex Launches"

Quick Search
Advertisement